Baseline serum estradiol and fracture reduction during treatment with hormone therapy

The Women's Health Initiative randomized trial

J. A. Cauley, A. Z. Lacroix, J. A. Robbins, J. Larson, R. Wallace, J. Wactawski-Wende, Zhao Chen, D. C. Bauer, S. R. Cummings, R. Jackson

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Introduction: The purpose of the study was to test the hypothesis that the reduction in fractures with hormone therapy (HT) is greater in women with lower estradiol levels. Methods: We conducted a nested case-control study within the Women's Health Initiative HT Trials. The sample included 231 hip fracture case-control pairs and a random sample of 519 all fracture case-control pairs. Cases and controls were matched for age, ethnicity, randomization date, fracture history, and hysterectomy status. Hormones were measured prior to randomization. Incident cases of fracture were identified over an average follow-up of 6.53 years. Results: There was no evidence that the effect of HT on fracture differed by baseline estradiol (E2) or sex hormone binding globulin (SHBG). Across all quartiles of E2 and SHBG, women randomized to HT had about a 50% lower risk of fracture, including hip fracture, compared to placebo. Conclusion: The effect of HT on fracture reduction is independent of estradiol and SHBG levels.

Original languageEnglish (US)
Pages (from-to)167-177
Number of pages11
JournalOsteoporosis International
Volume21
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Fracture Fixation
Women's Health
Estradiol
Hormones
Sex Hormone-Binding Globulin
Serum
Hip Fractures
Random Allocation
Therapeutics
Hysterectomy
Case-Control Studies
Placebos

Keywords

  • Fracture
  • Hormone therapy
  • Sex steroid hormones
  • Women's Health Initiative

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Cauley, J. A., Lacroix, A. Z., Robbins, J. A., Larson, J., Wallace, R., Wactawski-Wende, J., ... Jackson, R. (2010). Baseline serum estradiol and fracture reduction during treatment with hormone therapy: The Women's Health Initiative randomized trial. Osteoporosis International, 21(1), 167-177. https://doi.org/10.1007/s00198-009-0953-7

Baseline serum estradiol and fracture reduction during treatment with hormone therapy : The Women's Health Initiative randomized trial. / Cauley, J. A.; Lacroix, A. Z.; Robbins, J. A.; Larson, J.; Wallace, R.; Wactawski-Wende, J.; Chen, Zhao; Bauer, D. C.; Cummings, S. R.; Jackson, R.

In: Osteoporosis International, Vol. 21, No. 1, 01.2010, p. 167-177.

Research output: Contribution to journalArticle

Cauley, JA, Lacroix, AZ, Robbins, JA, Larson, J, Wallace, R, Wactawski-Wende, J, Chen, Z, Bauer, DC, Cummings, SR & Jackson, R 2010, 'Baseline serum estradiol and fracture reduction during treatment with hormone therapy: The Women's Health Initiative randomized trial', Osteoporosis International, vol. 21, no. 1, pp. 167-177. https://doi.org/10.1007/s00198-009-0953-7
Cauley, J. A. ; Lacroix, A. Z. ; Robbins, J. A. ; Larson, J. ; Wallace, R. ; Wactawski-Wende, J. ; Chen, Zhao ; Bauer, D. C. ; Cummings, S. R. ; Jackson, R. / Baseline serum estradiol and fracture reduction during treatment with hormone therapy : The Women's Health Initiative randomized trial. In: Osteoporosis International. 2010 ; Vol. 21, No. 1. pp. 167-177.
@article{f37aa84feac64d95b0341577487a17b8,
title = "Baseline serum estradiol and fracture reduction during treatment with hormone therapy: The Women's Health Initiative randomized trial",
abstract = "Introduction: The purpose of the study was to test the hypothesis that the reduction in fractures with hormone therapy (HT) is greater in women with lower estradiol levels. Methods: We conducted a nested case-control study within the Women's Health Initiative HT Trials. The sample included 231 hip fracture case-control pairs and a random sample of 519 all fracture case-control pairs. Cases and controls were matched for age, ethnicity, randomization date, fracture history, and hysterectomy status. Hormones were measured prior to randomization. Incident cases of fracture were identified over an average follow-up of 6.53 years. Results: There was no evidence that the effect of HT on fracture differed by baseline estradiol (E2) or sex hormone binding globulin (SHBG). Across all quartiles of E2 and SHBG, women randomized to HT had about a 50{\%} lower risk of fracture, including hip fracture, compared to placebo. Conclusion: The effect of HT on fracture reduction is independent of estradiol and SHBG levels.",
keywords = "Fracture, Hormone therapy, Sex steroid hormones, Women's Health Initiative",
author = "Cauley, {J. A.} and Lacroix, {A. Z.} and Robbins, {J. A.} and J. Larson and R. Wallace and J. Wactawski-Wende and Zhao Chen and Bauer, {D. C.} and Cummings, {S. R.} and R. Jackson",
year = "2010",
month = "1",
doi = "10.1007/s00198-009-0953-7",
language = "English (US)",
volume = "21",
pages = "167--177",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "1",

}

TY - JOUR

T1 - Baseline serum estradiol and fracture reduction during treatment with hormone therapy

T2 - The Women's Health Initiative randomized trial

AU - Cauley, J. A.

AU - Lacroix, A. Z.

AU - Robbins, J. A.

AU - Larson, J.

AU - Wallace, R.

AU - Wactawski-Wende, J.

AU - Chen, Zhao

AU - Bauer, D. C.

AU - Cummings, S. R.

AU - Jackson, R.

PY - 2010/1

Y1 - 2010/1

N2 - Introduction: The purpose of the study was to test the hypothesis that the reduction in fractures with hormone therapy (HT) is greater in women with lower estradiol levels. Methods: We conducted a nested case-control study within the Women's Health Initiative HT Trials. The sample included 231 hip fracture case-control pairs and a random sample of 519 all fracture case-control pairs. Cases and controls were matched for age, ethnicity, randomization date, fracture history, and hysterectomy status. Hormones were measured prior to randomization. Incident cases of fracture were identified over an average follow-up of 6.53 years. Results: There was no evidence that the effect of HT on fracture differed by baseline estradiol (E2) or sex hormone binding globulin (SHBG). Across all quartiles of E2 and SHBG, women randomized to HT had about a 50% lower risk of fracture, including hip fracture, compared to placebo. Conclusion: The effect of HT on fracture reduction is independent of estradiol and SHBG levels.

AB - Introduction: The purpose of the study was to test the hypothesis that the reduction in fractures with hormone therapy (HT) is greater in women with lower estradiol levels. Methods: We conducted a nested case-control study within the Women's Health Initiative HT Trials. The sample included 231 hip fracture case-control pairs and a random sample of 519 all fracture case-control pairs. Cases and controls were matched for age, ethnicity, randomization date, fracture history, and hysterectomy status. Hormones were measured prior to randomization. Incident cases of fracture were identified over an average follow-up of 6.53 years. Results: There was no evidence that the effect of HT on fracture differed by baseline estradiol (E2) or sex hormone binding globulin (SHBG). Across all quartiles of E2 and SHBG, women randomized to HT had about a 50% lower risk of fracture, including hip fracture, compared to placebo. Conclusion: The effect of HT on fracture reduction is independent of estradiol and SHBG levels.

KW - Fracture

KW - Hormone therapy

KW - Sex steroid hormones

KW - Women's Health Initiative

UR - http://www.scopus.com/inward/record.url?scp=72449210490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449210490&partnerID=8YFLogxK

U2 - 10.1007/s00198-009-0953-7

DO - 10.1007/s00198-009-0953-7

M3 - Article

VL - 21

SP - 167

EP - 177

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 1

ER -